Neel M Butala1, Eric Secemsky2, Dhruv S Kazi2, Yang Song3, Jordan B Strom2, Kamil F Faridi4, J Matthew Brennan5, Sammy Elmariah6, Changyu Shen2, Robert W Yeh7. 1. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA; Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. 2. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. 3. Baim Institute for Clinical Research, Boston, Massachusetts, USA. 4. Section of Cardiology, Department of Medicine, Yale School of Medicine, New Haven, Connecticut, USA. 5. Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA. 6. Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA. 7. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Electronic address: ryeh@bidmc.harvard.edu.
Abstract
OBJECTIVES: The aim of this study was to examine the applicability of pivotal transcatheter aortic valve replacement (TAVR) trials to the real-world population of Medicare patients undergoing TAVR. BACKGROUND: It is unclear whether randomized controlled trial results of novel cardiovascular devices apply to patients encountered in clinical practice. METHODS: Characteristics of patients enrolled in the U.S. CoreValve pivotal trials were compared with those of the population of Medicare beneficiaries who underwent TAVR in U.S. clinical practice between November 2, 2011, and December 31, 2017. Inverse probability weighting was used to reweight the trial cohort on the basis of Medicare patient characteristics, and a "real-world" treatment effect was estimated. RESULTS: A total of 2,026 patients underwent TAVR in the U.S. CoreValve pivotal trials, and 135,112 patients underwent TAVR in the Medicare cohort. Trial patients were mostly similar to real-world patients at baseline, though trial patients were more likely to have hypertension (50% vs 39%) and coagulopathy (25% vs 17%), whereas real-world patients were more likely to have congestive heart failure (75% vs 68%) and frailty. The estimated real-world treatment effect of TAVR was an 11.4% absolute reduction in death or stroke (95% CI: 7.50%-14.92%) and an 8.7% absolute reduction in death (95% CI: 5.20%-12.32%) at 1 year with TAVR compared with conventional therapy (surgical aortic valve replacement for intermediate- and high-risk patients and medical therapy for extreme-risk patients). CONCLUSIONS: The trial and real-world populations were mostly similar, with some notable differences. Nevertheless, the extrapolated real-world treatment effect was at least as high as the observed trial treatment effect, suggesting that the absolute benefit of TAVR in clinical trials is similar to the benefit of TAVR in the U.S. real-world setting.
OBJECTIVES: The aim of this study was to examine the applicability of pivotal transcatheter aortic valve replacement (TAVR) trials to the real-world population of Medicare patients undergoing TAVR. BACKGROUND: It is unclear whether randomized controlled trial results of novel cardiovascular devices apply to patients encountered in clinical practice. METHODS: Characteristics of patients enrolled in the U.S. CoreValve pivotal trials were compared with those of the population of Medicare beneficiaries who underwent TAVR in U.S. clinical practice between November 2, 2011, and December 31, 2017. Inverse probability weighting was used to reweight the trial cohort on the basis of Medicare patient characteristics, and a "real-world" treatment effect was estimated. RESULTS: A total of 2,026 patients underwent TAVR in the U.S. CoreValve pivotal trials, and 135,112 patients underwent TAVR in the Medicare cohort. Trial patients were mostly similar to real-world patients at baseline, though trial patients were more likely to have hypertension (50% vs 39%) and coagulopathy (25% vs 17%), whereas real-world patients were more likely to have congestive heart failure (75% vs 68%) and frailty. The estimated real-world treatment effect of TAVR was an 11.4% absolute reduction in death or stroke (95% CI: 7.50%-14.92%) and an 8.7% absolute reduction in death (95% CI: 5.20%-12.32%) at 1 year with TAVR compared with conventional therapy (surgical aortic valve replacement for intermediate- and high-risk patients and medical therapy for extreme-risk patients). CONCLUSIONS: The trial and real-world populations were mostly similar, with some notable differences. Nevertheless, the extrapolated real-world treatment effect was at least as high as the observed trial treatment effect, suggesting that the absolute benefit of TAVR in clinical trials is similar to the benefit of TAVR in the U.S. real-world setting.
Authors: Issa J Dahabreh; Sarah E Robertson; Eric J Tchetgen; Elizabeth A Stuart; Miguel A Hernán Journal: Biometrics Date: 2019-06-21 Impact factor: 2.571
Authors: Jordan B Strom; Yuansong Zhao; Kamil F Faridi; Hector Tamez; Neel M Butala; Linda R Valsdottir; Jeptha Curtis; J Matthew Brennan; Changyu Shen; Mike Boulware; Jeffrey J Popma; Robert W Yeh Journal: Circ Cardiovasc Interv Date: 2019-11-07 Impact factor: 6.546
Authors: Mohamad Alkhouli; David R Holmes; John D Carroll; Zhuokai Li; Taku Inohara; Andrzej S Kosinski; Molly Szerlip; Vinod H Thourani; Michael J Mack; Sreekanth Vemulapalli Journal: JACC Cardiovasc Interv Date: 2019-05-27 Impact factor: 11.195
Authors: Jeffrey J Popma; David H Adams; Michael J Reardon; Steven J Yakubov; Neal S Kleiman; David Heimansohn; James Hermiller; G Chad Hughes; J Kevin Harrison; Joseph Coselli; Jose Diez; Ali Kafi; Theodore Schreiber; Thomas G Gleason; John Conte; Maurice Buchbinder; G Michael Deeb; Blasé Carabello; Patrick W Serruys; Sharla Chenoweth; Jae K Oh Journal: J Am Coll Cardiol Date: 2014-03-19 Impact factor: 24.094
Authors: Jordan B Strom; Hector Tamez; Yuansong Zhao; Linda R Valsdottir; Jeptha Curtis; J Matthew Brennan; Changyu Shen; Jeffrey J Popma; Laura Mauri; Robert W Yeh Journal: Am Heart J Date: 2019-03-06 Impact factor: 4.749
Authors: Haidong Lu; Stephen R Cole; H Irene Hall; Enrique F Schisterman; Tiffany L Breger; Jessie K Edwards; Daniel Westreich Journal: Clin Trials Date: 2018-10-17 Impact factor: 2.486